Authors
Loading...
Suggests GP IIb/IIIa as antithrombotic target; leaves open prospective trials in cardiovascular disease.
Key points are not available for this paper at this time.
Newman et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: